CVS Health Corp

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: CVS-1 Category:

Description

CVS Health Corporation managed to exceed analyst expectations in terms of revenue as well as earnings. The company showcased robust performance, affirming the strength of its diversified business model. Notably, the company achieved an adjusted EPS of $2.21 and an adjusted operating income close to $4.5 billion. Quarter revenues surged by nearly 11% to almost $90 billion compared to the previous year, underscoring the effectiveness of its operational strategies. CVS Health demonstrated its integrated model’s prowess, demonstrating significant progress in restoring its Medicare Advantage Star rating. Financially, the Health Care Benefits segment reported revenue growth exceeding $26 billion. In the Health Services segment, revenues surged to nearly $47 billion, reflecting an 8% increase. The company’s care delivery assets, including Signify and Oak Street, are experiencing accelerated growth. The Pharmacy & Consumer Wellness segment achieved nearly $29 billion in revenues, with the retail pharmacy business demonstrating robust performance. Besides, CVS Health introduced Cordavis, a wholly-owned subsidiary poised to tap into the burgeoning biosimilar market. By collaborating directly with manufacturers, CVS Health aims to bring a portfolio of biosimilar products to market, contributing to substantial savings for consumers and the broader healthcare system.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!